When trial results come in for a company in the health care space, it's often do or die, make or break. In this video, Motley Fool health care analyst David Williamson takes us through three such results just in, and what's happened with shares as a result. Tranzyme (NASDAQ:TZYM) was today's biggest loser, with shares down a devastating 75% after results came in that its drug TZP-102 was no better than a placebo in helping gastroparesis patients. AcelRX (NASDAQ:ACRX), on the other hand, was up after excellent results with its drug sufentanil nanotab pca in comparison with intravenous morphine for treating post-operative pain, and Threshold Pharmaceuticals (NASDAQ:THLD) experienced a jump up that has now settled back down, after some initial excitement about the results of its drug TH302 applied to maintenance therapy for soft-tissue sarcoma.
David Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.